Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Once Daily Dosing Compared to Twice Daily Dosing of Nitisinone in HT-1

Study Design Characteristics:
- Allocation: None
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients of all ages diagnosed with HT-1.~* Patients currently well-controlled, as judged by the investigator, on twice daily (or more frequent) dosing with Orfadin.~* Stable lab values, including liver values \<2 ULN (ALP, ALT, AST, bilirubin, INR).~* Women of childbearing potential willing to use adequate contraception~* Signed informed consent/assent.~Exclusion Criteria:~* Patients who have been previously treated with once daily Orfadin, even if later converted to twice daily dosing.~* Any medical condition which in the opinion of the investigator makes the patient unsuitable for inclusion.~* Enrollment in another concurrent clinical interventional study within three months prior to inclusion in this study.~* Pregnant women.~* Lactating women.~* Previous liver transplantation.~* Patients who have recently (past 4 weeks prior to inclusion) started any new medication for a previously undiagnosed illness/disease.~* Known hepatitis B, hepatitis C or HIV infection.~* Foreseeable inability to cooperate with given instructions or study procedures.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nitisinone treatment group (Type: EXPERIMENTAL): All patients in the study will first be put on twice daily dosing of nitisinone for 4 weeks. This will then be followed by once daily dosing of nitisinone for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).